AX-2025-020779 · Selank · CPC lot CPC-2504-F9844

Section 1

Results

Measured against the index acceptance specification for the neuroactive and cognitive peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 35 min gradient, 214 nm	98.88	% area	≥ 99.0	FAIL
Total impurities	RP-HPLC, sum of reported peaks	1.12	% area	≤ 1.0	FAIL
Largest single impurity	RP-HPLC — des-Thr (−101 Da)	0.41	% area	≤ 1.00	PASS
Identity	not ordered on this submission	not determined	—	required for VERIFIED status	NOT TESTED
Total peptide content	by difference from the gravimetric mass balance	84.03	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	83.09	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	25.74	mg	20 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	21.387	mg	20 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	106.9	%	90.0 – 110.0	PASS
Water content	Karl Fischer, coulometric, duplicate	9.37	%	≤ 12.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	6.30	%	≤ 10.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.30	%	—	NOT TESTED
Endotoxin	kinetic chromogenic LAL	2.15	EU/mg	≤ 5.0	PASS
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	5.58	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 35 min gradient	7.52	min	7.40 ± 0.25 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	0.94	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	54,952	—	≥ 20,000	PASS
Resolution to nearest impurity	vs diketopiperazine (−18 Da)	1.60	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 35 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 54,952, and skew follows the reported asymmetry factor of 0.94. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.41 % impurity against a 98.88 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	Selank — main peak	7.52	4,805,875	98.88	—
2	des-Thr (−101 Da)	7.22	19,927	0.41	-101.048
3	diketopiperazine (−18 Da)	7.73	19,927	0.41	-18.011
4	tuftsin fragment (−417 Da)	6.80	9,235	0.19	-417.235
5	acetyl adduct (+42 Da)	7.92	5,346	0.11	+42.011
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	9.37
Counter-ion (acetate)	ion chromatography	6.30
Residual solvent + inorganic residue	estimated	0.30
Total peptide content	by difference	84.03
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	98.40	98.88	divergence -0.55 pp vs batch median
Total impurities (% area)	1.60	1.12
Largest single impurity (% area)	0.92	0.41
Water (%)	8.3	9.37
Counter-ion (%)	not stated	6.30
Peptide content (%w/w)	86.9	84.03
Endotoxin (EU/mg)	not stated	2.15
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Laboratory-retained
Evidentiary weight: Provenance documented, selection uncontrolled.
Chain of custody: Laboratory retained sample (−20 °C, 19 d since original receipt) → re-assay.
Assay date: 20 Apr 2025
Submitted to the index: 11 May 2025
Laboratory: Nordanalyt Laboratories, Uppsala, Sweden
Method basis: 35 min gradient · high-resolution MS
Verification status: PURITY ONLY

What this report does not establish

That the compound is the compound named. No identity confirmation was ordered on this submission. A purity figure describes chromatographic homogeneity of whatever eluted; it does not name it.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 3

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

thin_coverage11 May 2025

Coverage on this compound is thin enough that one record moves the class median visibly. That is a statement about the index rather than about the material, and it is why the n= badge sits beside every aggregate.

kf_titrand11 May 2025

Water at 9.37 % is the largest non-peptide slot on most records and the one most often missing. Where it is present the balance can be closed; where it is not, nothing can.

ms_confirm11 May 2025

Two instruments or it is not confirmed. Zero instruments is a different conversation, and this record is that conversation.

Section 7

Related records

Same batch — lot CPC-2504-F9844 n=7

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Result
AX-2025-020778	CPC-2504-F9844	Janoshik	2025-Q2	98.84	8.86	—	Laboratory-retained	FAIL
AX-2025-020780	CPC-2504-F9844	PeptideMeter	2025-Q2	98.90	9.18	—	Buyer-sourced	FAIL
AX-2025-020781	CPC-2504-F9844	Janoshik	2025-Q2	99.69	9.41	—	Supplier-supplied	PASS
AX-2025-020782	CPC-2504-F9844	Nordanalyt	2025-Q2	99.09	9.65	—	Buyer-sourced	PASS
AX-2025-020783	CPC-2504-F9844	Janoshik	2025-Q2	99.12	8.87	100.9	Buyer-sourced	PASS
AX-2025-020784	CPC-2504-F9844	Janoshik	2025-Q2	98.95	9.26	—	Buyer-sourced	FAIL

Batch rollup and reproducibility assessment →

Cross-sections

Other recent Selank records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042858	GGPeps	GGPE-2603-J2447	VendorInvestigate	2026-Q3	98.87	8.85	99.4	Buyer-sourced	0	FAIL
AX-2026-042859	GGPeps	GGPE-2603-J2447	PeptideMeter	2026-Q3	98.92	9.48	103.5	Buyer-sourced	0	FAIL
AX-2026-041759	TFS	TFS-{CAT}-1712	Janoshik	2026-Q2	99.93	8.13	102.2	Buyer-sourced	0	PASS
AX-2026-042912	GGPeps	GGPE-2601-J3130	Janoshik	2026-Q2	99.75	9.44	89.7	Buyer-sourced	1	MARGINAL
AX-2026-041760	TFS	TFS-{CAT}-1712	Janoshik	2026-Q2	99.82	7.70	—	Buyer-sourced	0	PASS
AX-2026-041752	TFS	TFS-{CAT}-1712	Medutest	2026-Q2	99.63	7.43	—	Buyer-sourced	1	FAIL
AX-2026-042915	GGPeps	GGPE-2601-J3130	PeptideMeter	2026-Q2	99.53	10.03	—	Buyer-sourced	0	PASS
AX-2026-042910	GGPeps	GGPE-2601-J3130	VendorInvestigate	2026-Q2	99.62	9.21	105.0	Buyer-sourced	0	PASS

Other recent CPC records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043319	BPC-157	CPC-2602-W1610	Medutest	2026-Q3	98.82	2.88	103.5	Buyer-sourced	2	MARGINAL
AX-2026-043295	Liraglutide	CPC-2602-G9942	Janoshik	2026-Q3	97.34	5.17	106.3	Buyer-sourced	0	FAIL
AX-2026-043288	Tirzepatide	CPC-2607-L1516	Janoshik	2026-Q3	96.89	5.11	101.1	Laboratory-retained	0	FAIL
AX-2026-043327	N-Acetyl Semax Amide	CPC-2602-D1905	Nordanalyt	2026-Q3	99.05	5.67	90.6	Buyer-sourced	1	FAIL
AX-2026-043328	N-Acetyl Semax Amide	CPC-2602-D1905	Janoshik	2026-Q3	99.49	6.83	100.9	Supplier-supplied	0	PASS
AX-2026-043257	L-Carnosine	CPC-2603-G9615	VendorInvestigate	2026-Q3	98.20	10.41	102.2	Buyer-sourced	0	FAIL
AX-2026-043297	Liraglutide	CPC-2602-G9942	Janoshik	2026-Q3	97.01	4.95	103.5	Buyer-sourced	0	FAIL
AX-2026-043331	N-Acetyl Semax Amide	CPC-2602-D1905	Janoshik	2026-Q3	99.46	6.22	—	Supplier-supplied	0	PASS